Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Total Current Liabilities (2016 - 2026)

Intellia Therapeutics has reported Total Current Liabilities over the past 12 years, most recently at $76.4 million for Q1 2026.

  • Quarterly Total Current Liabilities fell 32.11% to $76.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $76.4 million through Mar 2026, down 32.11% year-over-year, with the annual reading at $103.9 million for FY2025, 6.29% down from the prior year.
  • Total Current Liabilities was $76.4 million for Q1 2026 at Intellia Therapeutics, down from $103.9 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $131.1 million in Q3 2022 and troughed at $76.4 million in Q1 2026.
  • The 5-year median for Total Current Liabilities is $105.1 million (2024), against an average of $107.0 million.
  • Year-over-year, Total Current Liabilities skyrocketed 107.75% in 2022 and then tumbled 32.11% in 2026.
  • A 5-year view of Total Current Liabilities shows it stood at $126.6 million in 2022, then dropped by 8.97% to $115.2 million in 2023, then fell by 3.78% to $110.9 million in 2024, then dropped by 6.29% to $103.9 million in 2025, then decreased by 26.41% to $76.4 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Total Current Liabilities are $76.4 million (Q1 2026), $103.9 million (Q4 2025), and $93.7 million (Q3 2025).